Determination of psychotropic use in children and adolescents from a prescription database: methodological issues

This is a preview of subscription content, log in to check access.

References

  1. Bachmann CJ, Manthey T et al (2013) Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 34(9):2551–2563

    PubMed  Article  Google Scholar 

  2. Bachmann CJ, Lempp T et al (2014) Use of antipsychotic medication in German children and adolescents, 2005–2012. Dtsch Arztebl Int 111(3):25–34

    PubMed Central  PubMed  Google Scholar 

  3. Grinker RR, Yeargin-Allsopp M, Boyle C (2011) Culture and autism spectrum disorders: the impact on prevalence and recognition. In: Amaral D, Dawson G, Geschwind D (eds) Autism spectrum disorders. Oxford University Press, Oxford, pp 112–136

    Google Scholar 

  4. Hoffmann F, Bachmann C (2014) Auch bei Kindern und Jugendlichen gibt es Unterschiede in Soziodemographie, Gesundheit und Inanspruchnahme zwischen den Krankenkassenarten [Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 57(4):455–463

    CAS  Article  Google Scholar 

  5. Hsia Y, Wong AY, Murphy DG, Simonoff E, Buitelaar JK, Wong IC (2014) Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology (Berlin) 231(6):999–1009

    CAS  Article  Google Scholar 

  6. Murray ML, Hsia Y et al (2014) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berlin) 231(6):1011–1021

    CAS  Article  Google Scholar 

  7. Rijcken CA, Boelema GJ et al (2003) Off-label use of antipsychotics in the community pharmacy: the sex differences. Pharmacopsychiatry 36(5):187–191

    CAS  PubMed  Article  Google Scholar 

  8. Rubin D (2013) Conflicting data on psychotropic use by children: two pieces to the same puzzle. JAMA Pediatr 167(2):189–190

    PubMed  Article  Google Scholar 

  9. Wong IC, Murray ML et al (2004) Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 89(12):1131–1132

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  10. Zoëga H, Baldursson G et al (2009) Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 19(6):757–764

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

Dr Bachmann has received lecture fees from Actelion, Novartis, and Ferring as well as payment from BARMER GEK for writing a chapter in a book. He has served as a study physician in clinical trials for Shire and Novartis. Dr Hoffmann is active on behalf of a number of statutory health-insurance companies (BARMER GEK, DAK, TK and various corporate health-insurance funds) in the setting of contracts for third-party payment.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christian J. Bachmann.

Additional information

Comment on: Hsia Y, Wong AY, Murphy DG, Simonoff E, Buitelaar JK, Wong IC (2014) Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology (Berl), 231(6): 999–1009.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bachmann, C.J., Hoffmann, F. Determination of psychotropic use in children and adolescents from a prescription database: methodological issues. Psychopharmacology 231, 3809–3811 (2014). https://doi.org/10.1007/s00213-014-3691-2

Download citation

Keywords

  • Autism Spectrum Disorder
  • Autism Spectrum Disorder
  • Risperidone
  • Methylphenidate
  • Rett Syndrome